| 生物活性 |
Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC50 of 6 nM that disrupts the MDM2-p53 interaction to stabilize and activate p53, thereby inducing cell cycle arrest, apoptosis, and reduced cancer cell viability, while downregulating EGFR protein expression and phosphorylation and inhibiting downstream signaling through SHP2, MEK1/2, ERK1/2, AKT, mTOR, p70 (S6K1), and S6, and also induces mitochondrial ROS production, promotes p38 MAPK phosphorylation, upregulates NOXA expression, and mediates caspase-3-dependent apoptosis and gasdermin E-dependent pyroptosis, and can be used for research on TP53-mutant non-small cell lung cancer, T-cell acute lymphoblastic leukemia, colorectal cancer, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematologic malignancies. |
体内研究 (In Vivo) |
Idasanutlin (40 mg/kg;口服;采用连续给药 5 天、停药 2 天的每日给药方案,持续 14 天) 单独处理可降低 T-ALL PDX 异种移植模型中的肿瘤负荷。 Idasanutlin (50-200 mg/kg;口服;每日;14 天) 在 50 mg/kg 剂量下可与抗 PD-1 协同作用,显著抑制 BALB/c 小鼠体内 CT26 肿瘤的生长;而更高剂量 (100 和 200 mg/kg) 无法控制肿瘤进展,且 200 mg/kg 剂量会降低循环 T 细胞数量。 Idasanutlin (200 mg/kg,口服,每日 1 次,连续 14 天) 与抗 PD-1 联合使用时,在侵袭性 B16-F10/C57BL/6 黑色素瘤小鼠模型中产生显著的效果;而 100 mg/kg Idasanutlin 单独使用或与抗 PD-1 联合使用均无此效果。 Idasanutlin (30 mg/kg;口服;第 13-17 天、第 20-24 天、第 27-29 天) 单独处理可使携带皮下 DoHH-2 弥漫大 B 细胞淋巴瘤 (DLBCL) 肿瘤的雌性 SCID beige 小鼠达到 56% 的肿瘤生长抑制率。 Idasanutlin (80-100 mg/kg;口服;第 18-22 天、第 25-36 天) 单独处理可使皮下接种 Z-138 MCL 肿瘤的雌性 SCID beige 小鼠的肿瘤生长抑制率达到 67%。 Idasanutlin (10 μmol/L) 可抑制 SFTSV 复制,并降低 SFTSV 感染的小鼠肝胆管类器官的细胞死亡。 Idasanutlin (25 mg/kg/天;口服;每日给药;最长三周) 单独处理可显著抑制 KCNR 神经母细胞瘤异种移植物的生长。 Idasanutlin (25 mg/kg/day;口服;每日给药;持续三周) 单药或与维奈托克联合使用,因 BCL-2 依赖性较低且受 MCL-1 介导的作用影响,无法显著抑制 KP-N-YN 神经母细胞瘤异种移植物的生长。 Idasanutlin (25 mg/kg/day;口服;每日给药;共 10 天) 单药可显著抑制 CHOA-NBX-4 来源神经母细胞瘤异种移植物的生长。 Idasanutlin (12.5-50 mg/kg;口服) 在裸鼠已建立的 SJSA1 骨肉瘤异种移植物模型中展现出强大的体内药效,12.5 mg/kg 剂量下的肿瘤生长抑制率达 88%,25 mg/kg 剂量下的肿瘤生长抑制率超过 100%。 Idasanutlin (RG7388) (1.11-200 mg/kg;口服;每日、每周 1 次、每周 2 次、间歇性给药、单次给药) 在 SJSA 骨肉瘤异种移植物中可诱导强效且统计学等效的抗肿瘤活性、细胞凋亡及抗增殖作用,其中连续每日给药方案 (如每日 30 mg/kg 可产生>100% TGI) 与多种间歇性给药方案 (如每周 2 次 50 mg/kg 可产生 96% TGI,给药 5 天/停药 23 天的 80 mg/kg 方案可产生>100% TGI) 均能达到该效果。 Idasanutlin (30 mg/kg;口服;每日一次;连续 21 天) 可使皮下接种 MV4-11 AML 异种移植物的雌性裸鼠肿瘤生长抑制率达到 30%。 Idasanutlin (30 mg/kg;口服;每日一次;连续 21 天) 可使原位移植 MV4-11 AML 异种移植物的雌性 NOD/SCID 小鼠寿命延长 35%。 Idasanutlin (30 mg/kg;口服;每日一次;连续 21 天) 可使携带原位 MOLM-13 AML 异种移植物的雌性 NOD/SCID 小鼠寿命延长 10%。
| Animal Model: |
NSG mice (immunodeficient) |
| Dosage: |
40 mg/kg |
| Administration: |
p.o.; daily on a 5-days-on 2-days-off schedule; 14 days |
| Result: |
Induced a significant decrease in T-ALL burden in 3 of 4 tested xenografts. Demonstrated synergistic tumor burden suppression. Significantly increased overall survival in the combination treatment group compared to single-agent or vehicle controls. |
| Animal Model: |
BALB/c (6- to 10-week-old; syngeneic subcutaneous colorectal carcinoma model via injection of 1×106 CT26 cells into a single flank) |
| Dosage: |
50 mg/kg; 100 mg/kg; 200 mg/kg |
| Administration: |
p.o.; daily; 14 days |
| Result: |
Slowed tumor growth in 2/8 mice at 50 mg/kg monotherapy. Significantly reduced tumor size when combined with anti-PD-1 at 50 mg/kg, with only 2/8 mice developing tumors ≥1000 mm3. Led to 6/8 mice being sacrificed before day 15, with all tumors reaching ≥1000 mm3 at 100 mg/kg monotherapy. Led to 4/8 mice surviving to day 15, with all tumors reaching ≥1000 mm3 at 200 mg/kg monotherapy. Caused a significant decrease in the proportion of TCR-positive T cells within the blood lymphocyte population between day 0 and day 7 at 200 mg/kg monotherapy, with the most pronounced decrease when combined with anti-PD-1. Did not affect PD-1 expression on CD4+ or CD8+ T cells across all doses of monotherapy. Showed no significant changes in CD69+ and CD25+ T cell populations across all groups. |
| Animal Model: |
C57BL/6 (syngeneic subcutaneous melanoma model via injection of B16-F10 cells into a single flank) |
| Dosage: |
100 mg/kg; 200 mg/kg |
| Administration: |
p.o.; daily; 14 days |
| Result: |
Provided some tumor growth control at 200 mg/kg monotherapy. Produced a significant therapeutic effect when combined with anti-PD-1 at 200 mg/kg. Showed no therapeutic effects at 100 mg/kg alone or combined with anti-PD-1. |
| Animal Model: |
SCID beige (female, bearing established subcutaneous human DoHH-2 tumors) |
| Dosage: |
30 mg/kg |
| Administration: |
p.o.; days 13-17, 20-24, 27-29 |
| Result: |
Achieved 56% tumor growth inhibition (TGI) with a normalized percent tumor control rate (npTCR) of 0.48. |
| Animal Model: |
SCID beige (female, bearing established subcutaneous human Z-138 tumors) |
| Dosage: |
100 mg/kg (days 18-22); 80 mg/kg (days 25-36) |
| Administration: |
p.o.; days 18-22, 25-36 |
| Result: |
Achieved 67% tumor growth inhibition (TGI) with a normalized percent tumor control rate (npTCR) of 0.43. |
| Animal Model: |
NMRI nu-/nu- (female, 6-15-weeks-old, 20-30 g, subcutaneous xenograft of BCL-2-dependent, p53 wild-type KCNR neuroblastoma cells) |
| Dosage: |
25 mg/kg/day (monotherapy; combination with 100 mg/kg/day venetoclax) |
| Administration: |
p.o.; daily; up to three weeks |
| Result: |
Resulted in an average tumor volume change of 186% after three weeks, compared with 512% for vehicle control. In combination with venetoclax, resulted in an average tumor volume change of -80%, with 1/6 complete remissions, 2/6 very good partial responses, and 3/6 partial regressions. Increased BAX levels in tumors, with more pronounced upregulation in combination-treated tumors. Mice receiving delayed combination therapy (one week venetoclax monotherapy followed by two weeks combination treatment) showed slightly less favorable responses, with 1 very good partial response, 3 partial regressions, and 3 no responses. |
| Animal Model: |
NMRI nu-/nu- (female, 6-15-weeks-old, 20-30 g, subcutaneous xenograft of BCL-2-expressing, p53 wild-type KP-N-YN neuroblastoma cells) |
| Dosage: |
25 mg/kg/day (monotherapy; combination with 100 mg/kg/day venetoclax) |
| Administration: |
p.o.; daily; three weeks |
| Result: |
Resulted in an average tumor volume change of 138% after three weeks, compared with 236% for vehicle control. In combination with venetoclax, resulted in an average tumor volume change of 97%. No statistically significant differences in tumor volume change were observed between treatment groups and vehicle control. BIM was already bound to MCL-1 in untreated xenografts, and complex levels increased upon combination treatment. |
| Animal Model: |
nu-/nu- athymic (female, 5-6-weeks-old, 18 g, subcutaneous patient-derived xenograft of BCL-2-dependent CHOA-NBX-4 tumor) |
| Dosage: |
25 mg/kg/day (monotherapy; combination with 100 mg/kg/day venetoclax) |
| Administration: |
p.o.; daily; 10 days |
| Result: |
Resulted in an average tumor volume change of 96% after 10 days, compared with 597% for vehicle control, and led to 1/4 stable disease. In combination with venetoclax, resulted in an average tumor volume change of -72%, with 5/6 partial regressions. Upregulated p53, MDM2, and BAX levels, and combination therapy increased cleaved PARP levels, indicating enhanced apoptosis. |
| Animal Model: |
nu-/nu- athymic (female, 5-6-weeks-old, 18 g, subcutaneous patient-derived xenograft of BCL-2-dependent, p53 wild-type COG-N-424x tumor) |
| Dosage: |
25 mg/kg/day (monotherapy; combination with 100 mg/kg/day venetoclax) |
| Administration: |
p.o.; daily; 4 days |
| Result: |
Resulted in an average tumor volume change of 185% after 4 days, compared with 216% for vehicle control. In combination with venetoclax, resulted in an average tumor volume change of 178%. No statistically significant differences in tumor volume change were observed between treatment groups and vehicle control, and no treatment responses were seen. Combination therapy led to enhanced PARP cleavage, and idasanutlin treatment upregulated p53 and MDM2 levels. |
| Animal Model: |
Nude mice |
| Dosage: |
12.5 mg/kg; 25 mg/kg; 50 mg/kg |
| Administration: |
p.o. |
| Result: |
Achieved 88% tumor growth inhibition with an AUC of 23 μg·h/mL. Achieved greater than 100% tumor growth inhibition with an AUC of 29 μg·h/mL. Resulted in mean tumor volumes near baseline through day 32 post-tumor cell implant. |
| Animal Model: |
Crl:NU-Foxn1nu (female, 10-12 weeks old, implanted with human SJSA osteosarcoma cells) |
| Dosage: |
1.11 mg/kg; 3.33 mg/kg; 10 mg/kg; 30 mg/kg; 50 mg/kg; 80 mg/kg; 100 mg/kg; 200 mg/kg |
| Administration: |
p.o.; daily (21 days, 28 days, 5 days); once weekly (21 days, 28 days); twice weekly (21 days); 5 days on / 23 days off (28-day cycle); 2 days on / 5 days off (4 cycles over 28 days); single dose |
| Result: |
Achieved 11% tumor growth inhibition (TGI), 0 partial regressions (PR), and 0% increase in lifespan (ILS) at 1.11 mg/kg daily. Achieved 50% TGI, 0 PR, and 25% ILS at 3.33 mg/kg daily. Achieved 77% TGI, 1 PR, and 25% ILS at 10 mg/kg daily. Achieved >100% TGI, 9 PR, and 125% ILS at 30 mg/kg daily for 21 days. Achieved >100% TGI, 7 PR, and 127% ILS at 30 mg/kg daily for 28 days. Achieved 79% TGI, 1 PR, and 32% ILS at 50 mg/kg once weekly. Achieved 96% TGI, 3 PR, and 57% ILS at 50 mg/kg twice weekly. Achieved >100% TGI, 6 PR, and 127% ILS at 80 mg/kg 5 days on/23 days off. Achieved >100% TGI, 9 PR, and 188% ILS at 100 mg/kg 2 days on/5 days off. Achieved >100% TGI, 7 PR, and 162% ILS at 200 mg/kg once weekly (split dose). Produced statistically significant increase in caspase 3/7 luminescence (max at 48 hours post-dose), increased cleaved PARP-1 (cPARP-1) levels, and reduced Ki-67 positive nuclei at 48 hours post-dose at single 80 mg/kg dose compared to vehicle. Produced statistically significant increase in caspase 3/7 luminescence (max at 48 hours post-dose), maximal increase in cPARP-1 levels, and maximal reduction in Ki-67 positive nuclei at 48 hours post-dose at single 200 mg/kg dose compared to vehicle. Produced statistically significant increase in caspase 3/7 luminescence and cPARP-1 levels, plus reduction in Ki-67 positive nuclei, with maximal effects observed on day 3 of dosing at 80 mg/kg daily for 5 days compared to vehicle. Showed statistical equivalence between 30 mg/kg daily and 50 mg/kg twice weekly; between 50 mg/kg once weekly and 10 mg/kg daily; and between multiple intermittent regimens and 30 mg/kg daily. |
| Animal Model: |
Nude mice (female, 7-week-old) bearing acute myeloid leukemia |
| Dosage: |
30 mg/kg |
| Administration: |
p.o.; daily; 21 days |
| Result: |
Achieved 30% tumor growth inhibition relative to vehicle control, with a treatment-to-control ratio (TCR) of 0.5 and 95% confidence interval (CI) of 0.26-0.98. |
| Animal Model: |
NOD/SCID mice (female, 10-week-old) |
| Dosage: |
30 mg/kg |
| Administration: |
p.o.; daily; 21 days |
| Result: |
Resulted in a median survival of 52 days post-inoculation, corresponding to a 35% increase in lifespan (ILS) relative to vehicle control (median survival 38.5 days).\nResulted in a median survival of 23 days post-inoculation, corresponding to a 10% increase in lifespan (ILS) relative to vehicle control (median survival 21 days). |
|